^
Association details:
| Biomarker: | ER L536H + ER D538G + CCND1 amplification |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
Published date:
01/06/2021
Excerpt:
The IMX-158 PDX model harbored two ESR1 mutation sites in L536H and D538G (Fig. 5a), with CCND1 amplification (Fig. 5b). The donor of the IMX-158 model was treated with fulvestrant and the CDK4/6 inhibitor palbociclib. After 4 months of treatment, the patient achieved partial response by RECIST 1.1
Secondary therapy:
fulvestrant
DOI:
10.1186/s12967-020-02607-2
